Cholesterol and cardiovascular disease in the elderly. Facts and gaps

Aging and Disease

Volumn 4, Issue 3, 2013, Pages 154-169

  Félix Redondo, Francisco J ^a   Grau, Maria ^b   Fernández Bergés, Daniel ^c  

^a Centro de Salud Villanueva Norte   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL DON BENITO VILLANUEVA   (Spain)

Author keywords

Aged; Cardiovascular disease; Coronary artery disease; Hypercholesterolemia; Peripheral arterial disease; Stroke

Indexed keywords

EID: 84891892717     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III) (2002). Third report of the National Cholesterol Education Program (NCEP). Final report. Circulation, 106:3143-21
2. Stary HC, Chandler B, Glagov S, Guyton JR, Insull W, Rosenfeld ME et al (1994). A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb, 14:840-56
3. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W et al (1995). A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arterioclerosis, American Heart Association. Arterioscler Thromb Vasc Biol, 15:1512-31
4. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J et al (2006). The cardiovascular disease continuum validated: clinical evidence of improved patient outcome: Part I: Pathophysiology and clinical trial evidence (Risk factors through stable coronary disease). Circulation, 114:2850-70
5. Ross R (1999). Atherosclerosis: an inflammatory disease. N Eng J Med, 340:115-26
6. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB et al (2012). Heart disease and stroke statistic-2012 Update: A report from the American Heart Association. Circulation, 125:e2-e220
7. Grau M, Elosua R, Cabrera de Leon A, Guembe MJ, Baena-Diez, Vega-Alonso T, et al (2011). Cardiovascular risk factors in Spain in the first decade of the 21st century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study. Rev Esp Cardiol, 64:295-304
8. Levi F, Chatenoud L, Bertoccio P, Lucchini F, Negri E, La Vecchia C (2009). Mortality from cardiovascular and cerebrovascular disease in Europe and others areas of the world: an update. Eur J Cardiovasc Prev Rehabil, 16:333-50
9. Wang D Q-H, Cohen DE (2011). Absorción y excreción del colesterol y otros esteroles. In: Ballantyne. Lipidología Clínica. Barcelona: J & C Ediciones Medicas SL, 26-44 (Spanish Edition of Clinical Lipidology 2009)
10. Pownall HJ, Gotto AM (2011). Metabolismo de las lipoproteínas plasmáticas humanas. In: Ballantyne. Lipidología Clínica. Barcelona: J & C Ediciones Medicas SL, 1-10 (Spanish Edition of Ballantyne. Clinical Lipidology 2009)
11. He J, Gu D, Reynolds K, Wu X, Muntner P, Zhao J et al (2004). InterASIA Collaborative Group. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China. Circulation, 110:405-11.
12. Guallar-Castillón P, Gil-Montero M, León-Muñoz LM, Graciani A, Bayán-Bravo A, Taboada JM et al (2012). Magnitude and management of hypercholesterolemia in the adult population of Spain, 2008-2010: The ENRICA Study. Rev Esp Cardiol, 65:551-8.
13. Primatesta P, Poulter NR (2006). Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf), 64:292-8.
14. Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R (2010). Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex, 52:S44-53.
15. Khonputsa P, Veerman JL, Vos T, Aekplakorn W, Bertram M, Abbott-Klafter J et al (2012). Joint prevalence and control of hypercholesterolemia and hypertension in Thailand: third national health examination survey. Asia Pac J Public Health, 24:185-94.
16. Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M (2008). Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine, 34:36-51.
17. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M et al (2005). Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA, 294:1773-81.
18. de Souza LJ, Souto Filho JT, de Souza TF, Reis AF, Gicovate Neto C, Bastos DA et al. (2003). Prevalence of dyslipidemia and risk factors in Campos dos Goytacazes, in the Brazilian state of Rio de Janeiro. Arq Bras Cardiol, 81:249-64.
19. Capuano V, Bambacaro A, D'Arminio T, Del Regno B, Dantonio V, Lanzara C (2003). Changes in total serum cholesterol for cardiovascular disease in a Mediterranean area, 1989-1999. Eur J Epidemiol, 18:27-32.
20. Norman R, Bradshaw D, Steyn K, Gaziano T; South African Comparative Risk Assessment Collaborating Group (2007). Estimating the burden of disease attributable to high cholesterol in South Africa in 2000. S Afr Med J, 97:708-15.
21. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund et al (2011). The task force for the management of dyslipidaemia of the European Society of Cardiology and the European Atherosclerosis Society. ESC/EAS Guidelines for the management of dyslipidaemia. Eur Heart J, 32:1769-818
22. Church TS, Lavie CJ (2011). Ejercicio y lípidos. In: Ballantyne. Lipidología Clínica. Barcelona: J & C Ediciones Medicas SL, 232-9 (Spanish Edition of Ballantyne. Clinical Lipidology 2009)
23. Healy GN, Clark BK, Winkler EAH, Gardiner PA, Brown WJ, Matthews CE (2011). Measurement of adults' sedentary time in population-based studies. Am J Prev Med, 41:216-27
24. Sallinen J, Leinonen R, Hirvensalo M, Lyyra TM, Heikkinen E, Rantanen T (2009). Perceived constraints on physical exercise, among obese and non-obese older people. Prev Med, 49:506-10
25. Brunzell JD (2011). Dislipemia genética. In: Ballantyne. Lipidología Clínica. Barcelona: J & C Ediciones Medicas SL, 71-84 (Spanish Edition of Ballantyne. Clinical Lipidology 2009)
26. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P et al (2010). The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol, 56:1113-32
27. Huxley R, Barzi F, Woodward M (2006). Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ, 332:73-8
28. Ginsberg, HN, Zhang Y-L, Hernanadez-Ono A (2005). Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res, 36:232-40
29. Mathus-Vliegen EM (2012). Obesity management task force of the European Association for the Study of Obesity. Obes Facts, 5:460-83
30. Félix-Redondo FJ, Baena-Diez JM, Grau M, Tormo MA, Fernández-Bergés D (2012). Prevalence of obesity and cardiovascular risk in the general population of a health area in Extremadura (Spain). The Hermex study. Endocrinol Nutr, 59:160-8
31. Fernández-Bergés S, Cabrera de León A, Sanz H, Elosua R, Guembe MJ, Alzamora M, Vega-Alonso T et al (2012). Metabolic syndrome in Spain: prevalence and coronary risk associated with harmonized definition and WHO proposal. DARIOS study. Rev Esp Cardiol, 63:241-8
32. Bensenor IM, Olmos RD, Lotufo PA (2012). Hypothyroidism in the elderly: diagnosis and management. Clin Interv Aging, 7:97-111
33. Stone NJ (2011). Evaluación clínica para detectar causas genéticas y secundarias de dislipemia. In: Ballantyne. Lipidología Clínica. Barcelona: J & C Ediciones Medicas SL, 144-54 (Spanish Edition of Ballantyne. Clinical Lipidology 2009)
34. Peppa M, Betsi G, Dimitriadis G (2011). Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease. J Lipids, 2011:575840. doi:10.1155/2011/575840
35. Cappola AR, Ladenson PW (2003). Hypothyroidism and aterosclerosis. J Clin Endocrinol Metab, 88:2438-44
36. Rodondi N, den Elzen WO, Bauer DC, Cappola AR, Razvi S, Walsh JP et al (2010). Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 304:1365-74
37. Bowling CB, Muntner P (2012). Epidemiology of chronic kidney disease among older adults: a focus on the oldest old. J Gerontol A Biol Sci Med Sci, 67:1379-86
38. Pritchard SS (2003). Impact of dyslipidaemia in end-stage renal disease. J Am Soc Nephrol, 14:S315-30
39. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, HammLL et al (2003). Kidney disease as a risk factor for the development of cardiovascular disease: A statement from the American Heart Association council on kidney in cardiovascular disease, high blood pressure research, clinical cardiology and epidemiology and prevention. Circulation, 108:2154-69
40. O'Donnell CJ, Elosua R (2008). Cardiovascular risk factors. Insights from Framingham Heart Study. Rev Esp Cardiol, 61:299-310.
41. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al (2009). American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 119:e21-181.
42. Yazdanyar A, Newman AB (2009). The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med, 25:563-77
43. Odden MC, Coxson PG, Moran A, Lightwood JM, Goldman L, Bibbins-Domingo K (2011). The impact of the aging population on coronary heart disease in the United States. Am J Med, 124:827-33.e5.
44. Moran A, Zhao D, Gu D, Coxson P, Chen CS, Cheng J et al (2008). The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China. BMC Public Health, 8:394.
45. Degano IR, Elosua R, Marrugat J (2012) Epidemiology of acute coronary syndromes in Spain: estimation of the number of cases and trends from 2005 to 2049. Rev Esp Cardiol (in press)
46. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al; Prospective Studies Collaboration (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 370:1829-39.
47. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D (1986). Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet, 2:933-6.
48. Aronow WS, Ahn C (1996). Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol, 77:864-6.
49. Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR (1990). High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med, 113:916-20.
50. Castelli WP, Wilson PW, Levy D, Anderson K (1989). Cardiovascular risk factors in the elderly. Am J Cardiol, 63:12H-19H.
51. Wong ND, Wilson PW, Kannel WB (1991). Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med, 115:687-93.
52. Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI et al (1994). Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA, 272:1335-40.
53. Corti MC, Guralnik JM, Salive ME, Harris T, Ferrucci L, Glynn RJ et al (1997). Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med, 126:753-60.
54. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD (2001). Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet, 358:351-5.
55. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R (2005). Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc, 53:219-26.
56. Brescianini S, Maggi S, Farchi G, Mariotti S, Di Carlo A, Baldereschi M; ILSA Group (2003). Low total cholesterol and increased risk of dying: are low levels clinical warning signs in the elderly? Results from the Italian Longitudinal Study on Aging. J Am Geriatr Soc, 51:991-6.
57. Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW (2004). A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly. Chin Med J (Engl), 117:163-7.
58. Casiglia E, Mazza A, Tikhonoff V, Scarpa R, Schiavon L, Pessina AC (2003). Total cholesterol and mortality in the elderly. J Intern Med, 254:353-62.
59. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG (1997). Total cholesterol and risk of mortality in the oldest old. Lancet, 350:1119-23.
60. Reuben DB, Ix JH, Greendale GA, Seeman TE (1999). The predictive value of combined hypoalbuminemia and hypocholesterolemia in high functioning community-dwelling older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc, 47:402-6.
61. Aronow WS, Frishman WH (2010). Management of hypercholesterolemia in older persons for the prevention of cardiovascular disease. Cardiol Rev, 18:132-40.
62. Kronmal RA, Cain KC, Ye Z, Omenn GS (1993). Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med, 153:1065-73.
63. Kannel WB, D'Agostino RB, Sullivan L, Wilson PW (2004). Concept and usefulness of cardiovascular risk profiles. Am Heart J, 148:16-26.
64. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977). High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med, 62:707-14.
65. Zimetbaum P, Frishman WH, Ooi WL, Derman MP, Aronson M, Gidez LI et al (1992). Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. The Bronx Aging Study. Arterioscler Thromb, 12:416-23.
66. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RG (2003). High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med, 163:1549-54.
67. Marini C, Baldassarre M, Russo T, De Santis F, Sacco S, Ciancarelli I et al (2004). Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology, 62:77-81.
68. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB (1991). Probability of stroke: a risk profile from the Framingham Study. Stroke, 22:312-8.
69. O'Donell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P et al INTERSTROKE Investigators (2010). Risk factors for ischemic and intracerebral haemorraghic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet, 376:112-23
70. Asplund K, Karvanen J, Giampaoli S, Jousilahti P, Niemelä M, Broda G et al (2009). Relative risks for stroke by age, sex and population based on follow-up of 18 European population in the MORGAM Project. Stroke, 40:2319-26
71. Dyker AG, Weir CJ, Lees KR (1997). Influence of cholesterol on survival after stroke: retrospective study. BMJ, 314:1584-8
72. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J (2000). Better outcome after stroke with higher serum cholesterol levels. Neurology, 54:1944-9
73. Zuliani G, Cherubini A, Atti AR, Ble A, Vavalle C, Di Todaron F et al (2004). Low cholesterol levels are associated with short-term mortality in older patients with ischemic strokes. J Gerontol A Biol Sci Med, 59:293-7
74. Olsen TS, Christiensen RH, Kammersgaard LP, Andersen KK (2007). Higher total serum cholesterol level are associated with less severe strokes and lower all-cause mortality: ten-year follow-up of ischemic strokes in the Copenhagen Stroke Study. Stroke, 38:2646-51
75. Bihari-Varga M, Székely J, Gruber E (1981). Plasma high density lipoproteins in coronary, cerebral and peripheral vascular disease. The influence of various risk factors. Atherosclerosis, 40:337-45
76. Aronow WS, Ahn C (1994). Correlation of serum lipids with the presence or absence of atherothrombotic brain infarction and peripheral arterial disease in 1,834 men and women aged > or = 62 years. Am J Cardiol, 73:995-7
77. Milionis HJ, Liberopoulus E, Goudevenos J, Bairaktari ET, Seferiadis K, Elisaf MS (2005). Risk factors for first-ever acute ischemic non-embolic stroke in the elderly individuals. Int J Cardiol, 99:269-75
78. Ramos R, Quesada M, Solanas P, Subirana I, Sala J, Vila J et REGICOR investigators (2009). Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk. Eur J Vasc Endovasc Surg, 38:305-11
79. Félix-Redondo FJ, Fernández-Bergés D, Grau M, Baena-Diez JM, Mostaza JM, Vila J (2012). Prevalence and clinical characteristics of peripheral arterial disease in the study population Hermex. Rev Esp Cardiol, 65:726-33
80. Golomb BA, Dang TT, Criqui MH (2006). Peripheral arterial disease: morbidity and mortality implications. Circulation, 114:688-99
81. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al (1992). Mortality over a period of 10 years in patients with peripheral arterial disease. N Eng J Med, 326:381-386
82. WB Kanell (1994). Risk factors for atherosclerosic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk, 1:333-9
83. Hooi JD, Kester ADM, Stoffers HEJH, Overdijk MM, van Ree JW, Knottnerus JA (2001). Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol, 153:666-72
84. Dagenais GR, Maurice S, Robitaille NM, Gingras S, Lupien PJ (1991). Intermittent claudication in Quebec men from 1974-1986: The Quebec Cardiovascular Study. Clin Invest Med, 14:93-100
85. Tapp RJ, Balkau B, Shaw JE, Valensi P, Cailleau M, Eschwege E; DESIR Study Group (2007). Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: the DESIR study. Atherosclerosis, 190:84-9.
86. Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA et al (2012). Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA, 308:1660-7.
87. Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Goldbourt U (1994). Epidemiology of intermittent claudication in middle age men. Am J Epidemiol, 140:418-30
88. Kennedy M, Solomon C, Manolio TA, Criqui MH, Newman AM, Polak JF et al (2005) Risk factors for declining ankle-brachial index in men and women 65 years or older: the Cardiovascular Health Study. Arch Intern Med, 163:1896-902
89. Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA et al (1998). Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol, 81:333-5.
90. Mohler ER 3rd, Hiatt WR, Creager MA (2003). Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation, 108:1481-6.
91. Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM (2008). Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation, 117:823-31.
92. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW (2002). Prevalence and clinical correlates of PAD in the Framingham Offspring Study. Am Heart J, 143:961-5.
93. Pomrehn P, Duncan B, Weissfeld L, Wallace RB, Barnes R, Heiss G et al (1986). The association of dyslipoproteinemia with symptoms and signs of peripheral arterial disease. The Lipid Research Clinics Program Prevalence Study. Circulation, 73:I100-7.
94. Skilton MR, Chin-Dusting JP, Dart AM, Brazionis L, Lantieri O, O'Dea K, et al; D.E.S.I.R. Study Group (2011). Metabolic health, obesity and 9-year incidence of peripheral arterial disease: the D.E.S.I.R. study. Atherosclerosis, 216:471-6.
95. Doll R, Peto R, Boreham J, Sutherland I (2004). Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ, 328:1519-28
96. de Lorgeril M, Salen P, Martin Jl, Monjaud I, Delaye J, Memelle N (1999). Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction: Final Report of the Lyon Diet Heart Study. Circulation, 99:779-85
97. Vicent-Baudry S, Defoort C, Gerber M Bernard MC, Verger P, Helal O et al (2005). The Medi-RIVAGE study: reduction of cardiovascular disease risk factors after a 3-mo intervention with a Mediterranean-type diet or a low-fat diet. Am J Clin Nutr, 82:964-71
98. Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvadó L. Ruiz-Gutierrez V, Covas MI et al (2006). Effects of a Mediterranean-style diet on cardiovascular risk factors: A randomized trial. Ann Intern Med, 145-1-11
99. Hu FB, Bronner L, Willet WC, Stampfer MJ, Rexrode KM, Albert CM et al (2002). Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA, 287:1815-21
100. He K, Rimm EB, Merchant A, Rosner BA, Stampfer MJ, Willet WC (2002). Fish consumption and risk of stroke in men. JAMA, 288:3130-16
101. Gruppo Italiano per lo Studio della sopravivenza nell'infarto miocárdico (1999). Dietary supplementation with n-3 poluunsaturated acids and vitamin E after myocardial infarction. Lancet, 354:447-55
102. Dattilo AM, Kris-Etherton PM (1992). Effects of weight reduction on bloods lipids and lipoproteins: a meta-analysis. Am J Clin Nutr, 56:320-8
103. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS et al (2003). Effects of the amount and intensity of exercise on plasma lipoproteins. N Eng J Med, 347:1483-92
104. Kelley GA, Kelley KS (2006). Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trials. J Mens Health Gend, 3:61-70
105. Kelley GA, Kelley KS, Tran ZVU (2004). Aerobic exercise and lipids and lipoproteinas in women: A meta-analysis of randomized controlled trials. J Womens Health, 13:1148-64
106. Kelley GA, Kelley KS (2009). Impact of progressive resistance training on lipids and lipoproteins in adults: A meta-analysis of randomized controlled trials. Preventive Medicine, 48:9-19
107. Fonong T, Toth MJ, Ades PA, Katzel LI, Calles-Escandon J, Poehlman ET(1996). Relationship between physical activity and HDL-Cholesterol in healthy older men and women: a cross-sectional and exercise intervention study. Atherosclerosis, 127:177-183
108. Boardley D, Fahlman M, Topp R, Morgan AL, McNevin (2007). The impact of exercise training on blood lipids in older adults. Am J Geriatr Cardiol, 16:30-35
109. Kokkinos P (2012). Physical activity, health benefits and mortality risk. ISRN Cardiol, 2012:718789. doi: 10.5402/2012/718789
110. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279:1615-22
111. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower -than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 361:1149-58
112. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al (2008). Rosuvastatin to prevent vacular events in men and women with elevated C-reactive protein. N Engl J Med, 359:2195-207.
113. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM (2010). Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med, 152:488-96
114. Lemaitre RN, Psaty BM, Heckbert SR, Kronmal RA, Newman AB, Burke GL (2002). Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med, 162:1395-400.
115. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ et al (2009). The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ, 338:b2376
116. Scandinavian Simvastatin Survival Study group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344:1383-9.
117. Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O et al (1997). Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation, 96:4211-8.
118. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Coles TG et al (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med, 335:1001-9
119. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G Mitchell J et al (1998). Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med, 129:681-9
120. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study group (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 339:1349-57
121. The LIPID Study Group (2002). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet, 359:1379-87
122. Heart Protection Study Collaborative Group (2002). MCR/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet, 360:7-22.
123. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckey BM, Cobbe SM et al (2002). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 360:1623-30.
124. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators (2006). High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 355:549-59
125. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al; Cholesterol Treatment Trialists'(CTT) Collaborators (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366:1267-78
126. Cholesterol Treatment Trialists' Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376:1670-81
127. Roberts CG, Guallar E, Rodriguez A (2007). Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol Biol Sci Med Sci, 62:879-87.
128. Franssen R, Vergeer M, Stroes ES, Kastelein JJ (2009). Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab, 11:89-94
129. Ford I, Murray H, Packard CJ, Shepherd J, MacFarlane PW, Cobbe SM (2007). Long-term follow-up of the West of Scotland Coronary Prevention Study. N Eng J Med, 357:1477-86
130. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA et al (2011). Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM, 104:109-24.
131. Alberton M, Wu P, Druyts E, Briel M, Mills EJ (2012). Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM, 105:145-157
132. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol, 44:720-32.